UpdatesPlus-Psoriasis - An expert analysis of recent events in Psoriasis

Our December issue of UpdatesPlus-Psoriasis is now available.  This 121 slide report analyzes information from over the last couple of months, incorporating EADV presentations.  Key topics are shown below. The executive summary can be found here.  For information on receiving the full report or to meet us at Gene to Clinic this week please contact leaddisc@leaddiscovery.co.uk  

Key topics from the December issue of UpdatesPlus-Psoriasis include

• Current marketed products with sales figures (inc psoriasis splits), life cycle management studies and commercial activity.  In particular we look at Jansen's efforts to capture the market through messaging of Stelara drug survival
• Biosimilar activity as Remsima is filed in the US
  
• Analysis of the next market entries, Cosentyx and Otezla, including a detailed look at regulatory decisions including the surprising first line recommendation by the CHMP for Cosentyx.  We also look at new post hoc analyses, plus the novel SensoReady autoinjector device developed for Cosentyx
• New data on ixekizumab and brodalumab.  This includes new Phase 2 post hoc analyses and the recently announced Phase 3 data.  We take a critical and in depth look at the latter.
  
• The IL-23 class.  We ask if these candidates really offer a paradigm shift in psoriasis treatment in the wake of some astonishing preliminary data on BI 655066
  
• New data on taclonex gel/suspension as Leo fights to grow this segment
• Pipeline entries including novel JAKs, H4 blockers, PI3K
  

As usual we offer fully up to date charts summarizing the psoriasis landscape and clinical trial activity